Introduction
Prostate cancer is the most common malignancy and the second leading cause of cancer mortality in men (Landis et al., 1999) . Prostate cancer is unique among human cancers because of its striking age-dependent incidence and variable penetrance. The development of prostate cancer in humans has been viewed as a multistage process, involving the onset as small latent carcinoma of low histological grade to large metastatic lesion of higher grade (Long et al., 1997) . Unfortunately, there are limited treatment options available for this disease because chemotherapy and radiation therapy are largely ineective, and metastatic disease frequently develops even after potentially curative surgery (Petrylak, 1999; Pisters, 1999; Richie, 1999) . Thus, new ways of treating prostate cancer must be developed. Recently, TRAIL (TNF-Related-ApoptosisInducing-Ligand)/Apo-2L has been shown to be a potential candidate for cancer therapy (Srivastava, 2000) .
We and others have shown that TRAIL induces apoptosis in various cancer cells (Bodmer et al., 2000; Kim et al., 2000 Kim et al., , 2001 Suliman et al., 2001; Walczak et al., 1997) , but is less eective in nontransformed cells (French and Tschopp, 1999; Gura, 1997; Walczak et al., 1999) . The administration of Fas ligand and TNFa gave less encouraging results due to severe systemic toxicity (Nagata, 1997; Orlinick et al., 1999) , whereas administration of TRAIL was eective at reducing adenocarcinoma growth in rodents (Walczak et al., 1997) and non-human primates without any toxic eects. Taken together, these observations suggest that TRAIL may have considerable potential as a cancer therapeutic agent.
TRAIL induces apoptosis by binding to TRAIL-R1 (DR4/APO-2A) (Pan et al., 1997) and TRAIL-R2 (DR5/TRICK/Killer) (Pan et al., 1997; Schneider et al., 1997 ; Screaton et al., 1997; Sheridan et al., 1997; Walczak et al., 1997; Wu et al., 1997) . TRAIL receptors are expressed ubiquitously in cancer cells. Recently, based on in vitro experiments, some TRAIL resistant cancer cell lines have been discovered. The reason for the TRAIL resistance is unknown, but is not regulated solely by the dierential expression of the known TRAIL receptors DR4 and DR5 (Srivastava, 2000) . Instead, it appears that intracellular inhibitor(s) acting downstream of TRAIL receptors renders some cells insensitive to TRAIL . Furthermore, resistance of many types of cancer cells to TRAIL can be reversed by treatment with RNA synthesis inhibitors Mori et al., 1999) , protein synthesis inhibitors Rieger et al., 1999; Wajant et al., 2000) or chemotherapeutic agents (Ashkenazi and Dixit, 1999; Keane et al., 1999) . The study of the intracellular mechanisms that control TRAIL sensitivity may enhance our knowledge of death receptor-mediated signaling and help to develop TRAIL-based approaches to cancer treatment (Srivastava, 2000) .
We and others have reported that the binding of TRAIL to DR4 and DR5 leads to the cleavage and activation of caspase-8 (Ashkenazi and Dixit, 1999; Grith et al., 1999; Srivastava, 2000; Suliman et al., 2001) , that in turn activate downstream eector caspases such as caspase-3, and caspase-7 (Muzio, 1998; Suliman et al., 2001 ). Activation of caspase-8 by TRAIL may also cleave BID (a Bcl-2 inhibitory protein) whose cleavage product triggers mitochondrial depolarization (decrease in DCm) and subsequent release of cytochrome c from mitochondria (Luo et al., 1998; Suliman et al., 2001) . Once released into the cytosol, cytochrome c binds to Apaf-1 (apoptotic protease-activating factor 1) and, in the presence of dATP, recruits and activates procaspase-9 to form the apoptosome (Green and Reed, 1998) . Activated caspases cleave several downstream death substrates and activate endonucleases resulting in apoptosis (Green and Amarante-Mendes, 1998; Srivastava et al., 1999b) .
Akt promotes cell survival and blocks apoptosis (Hemmings, 1997; Kennedy et al., 1999; Kulik et al., 1997) . Activation of PI3K-Akt pathway generates phosphatidylinositol-3,4,5-triphosphate, which in turn binds to the pleckstrin homology domain of serine/ threonine kinase Akt, resulting in recruitment of Akt to the cell membrane. A conformational change of Akt results in phosphorylation of residues Thr-308 and Ser-473 by upstream kinases, PDK-1 and PDK-2 or ILK, respectively . Activated Akt phosphorylates speci®c targets such as Bad (del Peso et al., 1997), pro-caspase-9 (Cardone et al., 1998) , and transcription factor FKHRL1 (Brunet et al., 2001) at the Akt phosphorylation consensus sequence R-X-R-X-X-S/T, thus promoting cell survival and blocking apoptosis. The tumor suppressor gene PTEN/ MMAC1/TEP1 (for simplicity hereafter referred to as PTEN), which dephosphorylates 3'-phosphorylated phosphoinositides in vivo, inhibits AKT activation (Cantley and Neel, 1999) . Cowden disease patients, who have a germ line inactivating PTEN mutation, display increased breast cancer risks . Similarly, PTEN mutation is observed in endometrial cancer (Tonks and Myers, 1999) . Thus, the PI3K-Akt pathway plays a critical role in anti-apoptosis that may contribute to pathogenesis of cancer .
The purpose of this study is to investigate the intracellular mechanisms by which prostate cancer LNCap cells are resistant to TRAIL. We show that TRAIL induces apoptosis with variable responses in several prostate cancer cell lines, the LNCap cells being most resistant. TRAIL signals apoptosis through FADD and caspase-8. We have shown that TRAIL induces apoptosis by causing activation of caspases, cleavage of BID, loss of mitochondrial membrane potential, and release of cytochrome c from mitochondria (Kim et al., 2001; Suliman et al., 2001) . Interestingly, LNCap cells express a high constitutive active Akt, which is inversely correlated with TRAIL sensitivity. Furthermore, down-regulation of Akt with DN-Akt, inhibitors of PI-3 kinase (wortmannin and LY-294002) or PTEN made LNCap cells sensitive to TRAIL killing. Overexpression of constitutively active Akt in PC-3M cells restores TRAIL resistance. These data suggest that elevated Akt activity protects LNCap cells from TRAIL-induced apoptosis, and the PI-3 kinase/Akt pathway may inhibits apoptotic signals by inhibiting processing of BID.
Results

Effects of soluble human TRAIL on cell viability of prostate cancer cells
We ®rst tested the cytotoxic eect of TRAIL on four prostate cancer cell lines by trypan blue assay ( Figure  1 ). Cell viability assays demonstrated that PC-3, DU145 and PC-3M cells were sensitive to TRAIL, in a dose-and time-dependent manner, whereas LNCap cells were resistant (Figure 1a,b) . In order to con®rm whether cell death occurred via apoptosis, we used nucleosome ELISA assay. The data revealed that LNCap cells were resistant to apoptosis, whereas PC-3, DU145 and PC-3M cells were sensitive to TRAIL (data not shown).
Constitutively active Akt in prostate cancer cells, and inhibition of Akt activity and apoptosis by PI-3 kinase inhibitors Growth factors signaling through the phosphoinositide 3-kinase/Akt pathway promote cell survival (Downward, 1998; Sekulic et al., 2000; Stambolic et al., 1998) . Because AKT is a central regulator of many intracellular processes implicated in prostate tumor progression and because PTEN, the negative regulator of AKT (Persad et al., 2000; Weng et al., 2001) , is functionally inactivated in a signi®cant proportion of advanced human prostate cancer, we explored whether increased AKT activity may be involved in TRAIL resistance. To investigate the mechanisms controlling the resistance to LNCap cells to the cytotoxic eect of TRAIL, Akt activity was measured by Western blot analysis using phosphoactive Akt antibody, which recognizes the phosphorylation of Ser 473 at the C-terminus of Akt (Downward, 1998) . LNCap cells have the highest expression of constitutively active Akt among all the cells examined, whereas PC-3 cells possesses a moderate level (Figure 2a ). By comparison, DU-145 and PC-3M cells have low levels of constitutively active Akt (Figure 2a ). Total Akt levels in LNCap, PC-3, PC-3M and DU145 cells did not change. ERK2 was used as a loading control. We next examined whether constitutively active Akt can be down-regulated by inhibitors of PI-3 kinase (LY-294002 and wortmannin) and protein synthesis (cycloheximide). We have used the doses of LY-294002, wortmannin and cycloheximide as reported elsewhere (Downward, 1998; Sekulic et al., 2000; Stambolic et al., 1998) . Treatment of LNCap and PC-3 cells with LY-294002 (20 mM), wortmannin (200 nM), or cycloheximide (10 mM) for 8 h reversed the constitutive activity of Akt (Figure 2b ).
Since LNCap cells possess a high constitutively active Akt, we sought to examine whether downregulation of constitutively active Akt makes LNCap cells sensitive to TRAIL. LNCap and PC-3 cells were pre-treated with inhibitors of PI-3 kinase, LY-294002 (20 mM) and wortmannin (200 nM), or protein synthesis, cycloheximide (10 mM) for 45 min, followed by treatment with TRAIL (50 ng/ml), and apoptotic nuclei were counted by DAPI staining (Figure 2c ). TRAIL induced apoptosis in PC-3 cells, but had no 
TRAIL-mediated apoptosis is blocked at the level of BID cleavage, but not at the level of caspases-8, in LNCap cells
We have previously shown that TRAIL induced signaling requires formation of DISC, where FADD is a constituent of TRAIL-DISC (Kim et al., 2001; Suliman et al., 2001) . Furthermore, formation of DISC is essential for activation of caspases 8 (Srivastava, 2000; Suliman et al., 2001) . To rule out the possibility of defects in caspase-8, we examined the caspase-8 activity in LNCap cells and compared it with PC-3 cells ( Figure 3 ). TRAIL induced caspase-8 activity in LNCap and PC-3 cells. Pretreatment of cells with wortmannin or LY-294002 had no further eect on TRAIL-induced caspase-8 activity. These data suggest that defects in LNCap cells are not due to caspase-8 activity.
We have shown that treatment of cells with TRAIL results in BID (a BH3-domain-only molecule) cleavage at its amino terminus . Cleavage of cytosolic p22 BID by caspase-8 generates a p15 fragment that translocates to the mitochondria. Truncated p15 BID (tBID) inserts into the membrane and immunodepletion of tBID from subcellular fractions argues that tBID is required for cytochrome c release from the mitochondria. We therefore examined the eects of TRAIL on BID cleavage in LNCap and PC-3 cells (Figure 3b ). While ineective alone, TRAIL along with wortmannin or LY-294002 cleaved BID. Similarly, BID cleavage was enhanced in PC-3 cells when TRAIL was combined with wortmannin or LY-294002.
Mitochondria appear to play an important role in apoptosis (Kroemer and Reed, 2000; Suliman et al., 2001) . Both mitochondrial depolarization and the loss of cytochrome c from the mitochondrial intermembrane space have been proposed as early events in apoptotic cell death (Green and Reed, 1998; Kroemer and Reed, 2000) . The¯uorescent dye DiOC 6 (3) localizes to mitochondria and the MPT reduces the accumulation of DiOC 6 (3) as a consequence of the loss in mitochondrial membrane potential (Dc m ) (Srivastava et al., 1999b; Suliman et al., 2001) . If the high constitutive activity of Akt causes TRAIL resistance in LNCap cells, then Akt may block apoptosis either upstream (Datta et al., 1997; Kennedy et al., 1999) , or downstream (Snell et al., 1997) The PTEN tumor suppressor gene is frequently inactivated in primary human prostate cancers, particularly in the more advanced cancers (Ittmann, 1998) , and in human prostate cancer xenografts and cell lines including PC-3, Du145, and LNCap Vlietstra et al., 1998; Whang et al., 1998) . These studies suggest that components of the phosphatidylinositol 3-kinase pathway that are negatively regulated by PTEN, such as the key cell survival kinase AKT (Cantley and Neel, 1999; Stambolic et al., 1998; , may be increasingly activated with prostate tumor progression. We, therefore, transfected LNCap cells with either empty vector or PTEN cDNA ( Figure  4c ). Transfection of LNCap cells with PTEN cDNA resulted in apoptosis and in BID cleavage by TRAIL (Figure 4c,d ). These data con®rmed our previous ®ndings that constitutively active Akt may be involved in the inhibition of TRAIL signaling in LNCap cells.
Bcl-2 or Bcl-X L blocks wortmannin/LY-294002 plus TRAIL-induced drop in mitochondrial membrane potential and apoptosis in LNCap cells
We have previously shown that Bcl-2 did not inhibit TRAIL-induced apoptosis in Jurkat T cells, whereas it inhibited TRAIL-induced apoptosis in prostate cancer PC-3 cells (Kim et al., 2001; Srivastava, 2000; Suliman et al., 2001 In type II cells, mitochondrial cytochrome c release serves as an ampli®cation loop that potentiates the activation of caspases-3. We therefore extended these studies in LNCap cells to determine whether wortmannin/LY-294002 plus TRAIL-induced apoptosis can be blocked by Bcl-2 or Bcl-X L . We transfected LNCap cells with Bcl-2 (LNCap/Bcl-2), Bcl-X L (LNCap/Bcl-X) or empty vector (LNCap/Neo). Overexpression of Bcl-2 or Bcl-X L in LNCap cells inhibited wortmannin plus TRAIL or LY-294002 plus TRAIL induced apoptosis ( Figure  5a ). We next investigated whether Bcl-2 or Bcl-X L inhibits apoptosis at the level of mitochondria by measuring mitochondrial membrane potential. As expected, the Bcl-2 or Bcl-X L inhibited wortmannin plus TRAIL or LY-294002 plus TRAIL-induced Dc m . Thus, the inhibition of wortmannin plus TRAIL or LY-294002 plus TRAIL-induced apoptosis by Bcl-2 or Bcl-X L was correlated with inhibition of Dc m . Thus, although wortmannin plus TRAIL or LY-294002 plus TRAIL failed to kill Bcl-2-overexpressing LNCap cells, leukemic cells overexpressing Bcl-2 remain highly sensitive to TRAIL-induced apoptosis ).
Overexpression of constitutively active Akt in PC-3M cells confers TRAIL resistance
Since PC-3M cells express very low levels of constitutively active Akt, and TRAIL alone can kill these cells, we sought to examine the eects of the overexpression of constitutively active Akt on TRAIL-induced apoptosis and mitochondrial membrane potential. PC-3M cells were transfected with empty vector, WTAkt, CA-Akt and DN-Akt, and Akt activity was measured by the Western blot analysis with antiphosphoactive Akt antibody ( Figure 6a 
of three independent experiments
Inhibition of TRAIL/Apo-2L-induced apoptosis by Akt X Chen et al and carcinomas of the prostate, lung, endometrium, and head and neck (Cairns et al., 1997; Guldberg et al., 1997; Kohno et al., 1998; Kong et al., 1997; Liu et al., 1997; Okami et al., 1998; Rasheed et al., 1997; Steck et al., 1997; Tashiro et al., 1997; Teng et al., 1997) . PTEN is frequently inactivated in primary human prostate cancers, particularly in the more advanced cancers (Ittmann, 1998) , and in human prostate cancer xenografts and cell lines including PC-3, Du145, and LNCap Vlietstra et al., 1998; Whang et al., 1998) . Overproduction of PTEN can suppress colony formation in certain cells, growth in soft agar, and tumor formation in nude mice (Cheney et al., 1998; Furnari et al., 1997) . In the mouse loss of PTEN allele leads to hyperplasia and dysplasia in the skin, gastrointestinal tract, and prostate, as well as tumor formation (Di Cristofano et al., 1998) . These studies suggest that components of the phosphatidylinositol 3-kinase pathway that are negatively regulated by PTEN, such as the key cell survival kinase AKT (Cantley and Neel, 1999; Stambolic et al., 1998; , may be increasingly activated with prostate tumor progression. Indeed, activated AKT regulates a number of intracellular targets implicated in prostate tumor progression and androgen independence. For instance, AKT-dependent inactivation of pro-apoptotic proteins such as BAD and caspase-9 (Cardone et al., 1998; Datta et al., 1997) may suppress the normal apoptotic response. Additionally, AKT may enhance cell cycle progression by suppressing AFX/Forkhead transcription factor activity (Brunet et al., 1999; Kops and Burgering, 1999; Tang et al., 1999) , which would result in diminished expression of AFX target genes such as the cell cycle inhibitor p27Kip1 (Medema et al., 2000) . We have previously reported that activation of caspase-8 by TRAIL can lead to two signals: (i) a mitochondrial-independent signal that activates caspases downstream of caspase-8, and (ii) a mitochondrial-dependent caspase activation following BID cleavage resulting in translocation of truncated BID (tBID) to mitochondria ). It appears that the eects of Bcl-2/Bcl-X L are cell type speci®c. Bcl-2/ Bcl-X L does not block TRAIL-induced apoptosis in lymphoid cells, whereas these proteins abrogated TRAIL-induced apoptosis by acting at the level of mitochondria in prostate cancer cells. The outer mitochondrial membrane becomes permeable to apoptogenic factors such as cytochrome c, Smac/ DIABLO (a caspase activator) (Du et al., 2000; Verhagen et al., 2000) and apoptosis-inducing factor (AIF) (Susin et al., 1999) . Bcl-2/ Bcl-X L appears to maintain mitochondrial function resulting in TRAILresistance in PC-3, DU145, and PC-3M cells, whereas lymphoid cells (Jurkat, CEM, MOLT-4, and U937 cells) overexpressing Bcl-2 retain their sensitivity against TRAIL.
Increased Akt activity may play a profound role in the progression of human prostate cancers. Akt regulates many of the processes associated with metastatic progression, and the emergence of androgen-independent hPCa cells. The constitutively active AKT corresponds to increased activity of integrinlinked kinase, the kinase putatively responsible for the activation of AKT by phosphorylation at Ser-473 (Downward, 1998; Lynch et al., 1999) , and markedly reduced expression of the cell cycle inhibitor p27 Kip1 (Medema et al., 2000) . The increased AKT activity and the reduction in p27
Kip1 expression have been associated with prostate tumor progression. Akt inhibits the Oncogene Inhibition of TRAIL/Apo-2L-induced apoptosis by Akt X Chen et al activity of DEVD-targeted caspases without changing the steady-state levels of Bcl-2 and Bcl-X L . Akt inhibits apoptosis and the processing of procaspases to their active forms by delaying mitochondrial changes in a caspase-independent manner. Akt activation is sucient to inhibit the release of cytochrome c from mitochondria and the alterations in the inner mitochondrial membrane potential. However, Akt cannot inhibit apoptosis induced by microinjection of cytochrome c. Akt inhibits apoptosis and cytochrome c release induced by several proapoptotic Bcl-2 family members. Similar to our ®ndings, it has recently been reported that elevated constitutively active Akt in LNCap cells protect them from TRAIL-induced apoptosis (Nesterova et al., 2001) . Taken together, Akt promotes cell survival by intervening in the apoptosis cascade before cytochrome c release and caspase activation via a mechanism that is distinct from Bad phosphorylation.
Death receptors trigger caspase activation through formation of DISC. Upon ligation of the receptor, adaptor proteins such as FADD are recruited, and these in turn recruit procaspases (caspases-8 and probably caspase-10) . The involvement of FADD in TRAIL receptor-DISC has recently been con®rmed by several laboratories including ours (Bodmer et al., 2000; Kischkel et al., 2000; Sprick et al., 2000; Suliman et al., 2001) . Using caspase-8 de®cient Jurkat cells, we have shown that caspase-8 activation is essential for TRAIL-induced apoptosis . In this study, TRAIL activated caspases-8 in both LNCap and PC-3 cells, but only PC-3 cells were sensitive. This is perhaps a higher level of constitutively active Akt, which inhibited BID cleavage in LNCap cells but not in PC-3 cells. Caspase-3 can be activated either directly by caspase-8 or mitochondrial events (e.g. release of cytochrome c) leading to apoptosis. TRAIL can induce apoptosis in Jurkat cells even after blocking permeability transition pore (PTP) by cyclosporin A, suggesting cells can undergo apoptosis without engaging mitochondria . The active caspases-8 eciently cleaves procaspase-3 (and other executioner caspases) and apoptosis proceeds. It appears that the type I pathway does not require the involvement of mitochondria, and Bcl-2 should have no eect on the process. However, in some other cases Bcl-2 can inhibit death receptor-triggered apoptosis, and this has led to the idea that there are two dierent cell types. In`type I' cells, death receptor signaling is not blocked by Bcl-2, whereas in`type II' cells it is (Scadi et al., 1998) . The mechanism linking death receptor signaling to a Bcl-2 inhibitable pathway came with the ®nding that truncated BID (tBID) translocates to mitochondria to trigger Bax oligomerization and cytochrome c release (Green and Reed, 1998; Korsmeyer et al., 1999) .
The molecular mechanism of apoptosis has been well studied. The Bcl-2 family proteins play important roles in the regulation of apoptosis. Bcl-2 inhibits apoptosis against various toxic stresses through stabilization of DC m (Green and Reed, 1998; Kroemer and Reed, 2000) , blocking the release of apoptosis inducer proteins such as cytochrome c (Kluck et al., 1997; Srivastava et al., 1999b) and AIF (Susin et al., 1999) from mitochondria to cytoplasm and thus inhibits the subsequent apoptosis-executing signaling events. Because most clinically administered chemotherapeutic drugs mediate apoptosis mainly by inducing mitochondrial dysfunction, tumor cell resistance is likely to include overexpression of Bcl-2. We and others have shown that Bcl-2 cannot inhibit TRAIL-induced apoptosis in leukemic cells (Keogh et al., 2000; Kim et al., 2001; Suliman et al., 2001) , suggesting that tumor cells which have already acquired resistance to chemotherapeutic drugs by Bcl-2 can be killed by TRAIL. Thus, TRAIL may be a promising candidate for the treatment of patients carrying Bcl-2 positive leukemic cells. In contrast, Bcl-2 abrogated TRAILinduced mitochondrial dysfunction and apoptosis in prostate cancer cells, suggesting a dierential regulation of apoptosis by Bcl-2.
Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer. PTEN might regulate apoptosis by blocking activation of downstream targets of phosphatidylinositol 3-kinase such as Akt. Tumor cells lacking PTEN contain high levels of activated Akt, and downregulation of Akt make these cells sensitive to TRAIL. Thus, therapeutic strategies that target the PI3-kinase/Akt pathway may be useful for cancers lacking PTEN function. Cycloheximide, wortmannin and LY-294002 were purchased from Calbiochem (La Jolla, CA, USA). All other chemicals used were of analytical grade and were purchased from Fisher Scienti®c (Suwanee, GA, USA) or Sigma (St. Louis, MO, USA). The nucleosome ELISA assay kit was from Oncogene Research Products (Cambridge, MA, USA). The caspase-8 assay kit was purchased from Clontech Laboratories, Inc. (Palo Alto, CA, USA). TRAIL was purchased from Biomol (Plymouth Meeting, PA, USA). Akt1 cDNAs (wild type, constitutively active and dominant negative) were from Upstate Biotechnology Inc. (Lake Placid, NY, USA).
Materials and methods
Reagents
Cells and culture conditions
Prostate cancer LNCap, PC-3, PC-3M, and DU145 cells were obtained from the American Type Culture Collection (Rockville, MD, USA). Cells were cultured in RPMI 1640 tissue culture medium (BioWhittaker Inc., Walkersville, MD, USA)
Inhibition of TRAIL/Apo-2L-induced apoptosis by Akt X Chen et al supplemented with 2 mML-glutamine, 10% fetal bovine serum and 1% penicillin-streptomycin mixture at 378C with 5% CO 2 . Cells were transfected with pSFFVneo-Bcl-2, pSFFVneo-Bcl-X L or pSFFV-neo plasmids as we described elsewhere (Srivastava et al., 1999a,b; Suliman et al., 2001) .
Measurement of mitochondrial energization
Mitochondrial energization was determined by retention of 3,3'-dihexyloxacarbocyanine (DiOC 6 (3)) (Srivastava et al., 1999b) . Cells (5610 5 in 500 ml of complete RPMI 1640 medium) were loaded with 40 nM DiOC 6 (3) during the last 30 min of treatment, the cells isolated at 700 g for 10 min, the cell pellet resuspended and washed twice in PBS. Cells were lysed by addition of 600 ml of deionized water followed by mechanical homogenization. The concentration of retained DiOC 6 (3) was determined on a¯uorescence spectrometer at 480 nm excitation and 510 nm emission (Srivastava et al., 1999b) .
Subcellular fractionation
Mitochondria and cytosolic (S100) fractions were prepared by resuspending cells in 0.8 ml ice-cold buer A (250 mM sucrose, 20 mM HEPES, 10 mM KCl, 1.5 mM MgCl 2 , 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 17 mg/ml phenylmethylsulfonyl¯uoride, 8 mg/ml aprotinin, 2 mg/ml leupeptin, pH 7.4) (Srivastava et al., 1999b) . Cells were passed through an ice-cold cylinder cell homogenizer. Unlysed cells and nuclei were removed by centrifugation at 750 g for 10 min. The supernatant was spun at 10 000 g for 25 min, and the mitochondrial pellet resuspended in buer A. The supernatant was spun at 100 000 g for 1 h. The supernatant from this ®nal centrifugation represented the S100 fraction.
Western blot analysis
Cells were lysed in a buer containing 10 mM Tris-HCl (pH 7.6), 150 mM NaCl, 0.5 mM EDTA, 1 mM EGTA, 1% SDS, 1 mM sodium orthovanadate, and a mixture of protease inhibitors (1 mM phenylmethylsulfonyl¯uoride, 1 mg/ml pepstatin A, 2 mg/ml aprotinin). Lysates were sonicated for 10 s, centrifuged for 20 min at 12 000 g and stored at 7708C. Equal amounts of lysate protein were run on 10% SDS ± PAGE gels and electrophoretically transferred to nitrocellulose. Nitrocellulose blots were blocked with 10% nonfat dry milk in TBST buer (20 mM Tris-HCl (pH 7.4), 500 mM NaCl, and 0.01% Tween 20) and incubated with primary antibody in TBST containing 5% bovine serum albumin overnight at 48C. Immunoreactivity was detected by sequential incubation with horseradish peroxidase-conjugated secondary antibody and ECL reagents.
Nucleosome ELISA assay
The nucleosome ELISA allows quantitation of apoptotic cells in vitro by DNA anity-mediated capture of free nucleosomes followed by their anti-histone-facilitated detection. In this assay, mono-and oligo-nucleosomes are captured on precoated DNA-binding proteins. Cells (2610 6 ) were seeded into 24-well plates in the presence or absence of various drugs for 36 h (see ®gure legends). Cells were harvested for nucleosome ELISA assay according to the manufacturer's directions (Oncogene Research Products, Cambridge, MA, USA). Brie¯y, anti-histone 3 biotin-labeled antibody binds to the histone component of captured nucleosomes and is detected following incubation with streptavidin-linked horseradish peroxidase conjugate. HRP catalyzes the conversion of colorless tetramethylbenzidine to blue and addition of a stop solution changes the color to yellow, the intensity of which is proportional to the number of nucleosomes in the sample.
